Michael E Kelly, MD,PhD

Program director, Cancer, Children's Hospital of Wisconsin
Associate professor, the Medical College of Wisconsin

Office Locations

8915 W. Connell Ave
Milwaukee, WI 53226
414-955-4170 (office)
(877) 607-5280 (appointment)
414-266-2420 (clinic)


Best Doctors 2013Dr. Kelly is a Board Certified Pediatric Oncologist with special interests in the care of children and young adults with diagnosed with leukemia, lymphoma and vascular tumors/anomalies. Dr. Kelly is currently the Medical Director of the Pediatric Cancer Program at Children’s Hospital of Wisconsin and a leader in the Cancer Center at the Medical College of Wisconsin. He serves as the institutional principle investigator for Children’s Oncology Group (COG) and the COG Phase 1 and Pilot Consortium.

Dr. Kelly is committed to improve our understanding of cancer and vascular anomalies through enrollment of patients on clinical trials. He has a special interest in the development of “first in children therapies” for patients with rare and recurrent cancers. His care philosophy is patient and family centric and works with the child's pediatrician and parents to provide the best and most informed care possible.

Pediatric Hematology-Oncology
Areas of Interest
  • Cancer
  • Acute leukemia
  • Lymphoma

Education & Awards

  • 1993, University of Cincinnati (OH), MD
  • 1996, Washington University School of Medicine
  • 1999, Washington University School of Medicine
  • Southeast Wisconsin's Best Doctors
  • Cambridge Who's Who
  • Best Doctor's in America
  • Professional of the Year Representing Pediatric Hematology & Oncology, Cambridge Who's Who

Research & Publications

  • Leukemia, lymphoma, vascular anomalies and tumors, drug development and clinical trials for pediatric cancer and vascular anomalies
  • Infrastructure to Facilitate Clinical and Translational Research in Pediatric Oncology at Children's Hospital of Wisconsin, Midwest Athletes against Childhood Cancer (MACC Fund), principal investigator
  • 1000EUSA12: An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi) Following Allergy to Native E. Coli Asparaginase (Elspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (A Phase 2 Clinical Trial) Source: Jazz Pharmaceutical
  • Preventing Obesity in Children Diagnosed with Acute Lymphoblastic Leukemia: A Pilot Study
    Source: Circle of Hope